Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00110500 | Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy | PHASE1 | COMPLETED | 12 | — | — | Apr 1, 2005 | Jan 1, 2008 | Jun 8, 2011 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| hVEGF-A | GENETIC | - |
Inclusion Criteria: * Have a clinical diagnosis of Diabetes Mellitus Type I or II for at least 12 months prior to the study. * Have received a diagnosis of mild to moderate sensori-motor diabetic neuropathy from a neurologist (a doctor who specializes in disorders of the nervous system) or endocrin...